Hikma Pharmaceuticals Plc Hikma reaches licensing agreement with Celltrion
December 19 2017 - 4:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
19 December 2017
PRESS RELEASE
Hikma reaches licensing agreement with Celltrion for third
biosimilar product in the Middle East and North Africa
London, 19 December 2017 - Hikma Pharmaceuticals PLC (Hikma)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's /
BB+ S&P, both stable) announces that it has reached a licensing
agreement with South Korea-based Celltrion, Inc. and Celltrion
Healthcare, Inc (Celltrion) for the first biosimilar monoclonal
Antibody (mAb) in oncology to be granted European marketing
authorisation, Truxima(TM) (rituximab). Hikma now has exclusive
agreements with Celltrion for three biosimilar products -
Truxima(TM) (rituximab), Remsima(R) (infliximab) and Herzuma(R)
(trastuzumab) - in all its MENA markets.
Truxima(TM) is mAb biosimilar to Roche's MabThera(R)
(rituximab), which is used to treat patients with non-Hodgkin's
lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis,
granulomatosis with polyangiitis and microscopic polyangiitis.
Under the terms of the agreement, Hikma has the exclusive rights
to distribute and market Truxima(TM) (rituximab) in all of its MENA
markets, leveraging Hikma's strong local presence, biosimilar
expertise, sales and marketing capabilities and regulatory
expertise.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging
Markets said, "We are pleased to be adding Truxima(TM) to our
biosimilar and oncology portfolio, building on the success of our
partnership with Celltrion in the MENA region. Global partnerships
are an integral part of our strategy to enhance our portfolio in
key therapeutic areas and increase patients' access to
high-quality, affordable medicines."
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and +44 (0)20 7399 2760/
Director of Investor Relations +44 7776 477050
Virginia Spring +44 (0)20 3892 4389/
Investor Relations Manager +44 7973 679502
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical
group focused on developing, manufacturing and marketing a broad
range of both branded and non-branded generic and in-licensed
products. Hikma's operations are conducted through three
businesses: 'Injectables,' 'Generics' and 'Branded,' based
primarily in the Middle East and North Africa (MENA) region, where
it is a market leader, the United States and Europe. In 2016, Hikma
achieved revenues of $1,950 million and profit attributable to
shareholders of $155 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGGGAPUPMGPR
(END) Dow Jones Newswires
December 19, 2017 04:00 ET (09:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024